Every 8-K that Atrium Therapeutics, Inc. (RNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNA filings page.
Atrium Therapeutics reported second-quarter 2026 results and highlighted key R&D milestones. The company received FDA IND clearance for ATR 1072 for PRKAG2 syndrome and initiated Corventis, its first Phase 1/2 clinical trial and first clinical study targeting this disease. Atrium also achieved a second milestone payment under its global cardiovascular collaboration with Bristol Myers Squibb.
For the quarter ended June 30, 2026, Atrium generated $3.0 million in collaboration revenue and recorded a net loss of about $20.2 million, or $1.18 per share. For the first six months of 2026, collaboration revenue was $22.6 million, while the net loss totaled approximately $36.8 million. Operating expenses reflect continued investment in R&D and company build-out.
As of June 30, 2026, Atrium reported $72.3 million in cash and cash equivalents and $191.6 million in short-term investments, supporting its precision cardiology pipeline, including ATR 1072, ATR 1086 for PLN cardiomyopathy, and additional rare cardiomyopathy programs.
Atrium Therapeutics announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for ATR 1072, enabling initiation of the Corventis Phase 1/2 trial in PRKAG2 syndrome.
Corventis is an open-label, multicenter study enrolling approximately 37 participants, with multiple ascending dose cohorts followed by an expansion cohort at a recommended Phase 2 dose. The company expects first enrollment by the end of 2026 and initial proof-of-concept data in the second half of 2027. ATR 1072 uses small interfering RNA to silence mutant PRKAG2 messenger RNA with the goal of normalizing AMPK activity and reducing glycogen accumulation in this rare cardiomyopathy, which is estimated to affect 1,000–2,000 people in the U.S.
Atrium Therapeutics, Inc. reported first quarter 2026 results following its launch as a public precision cardiology company. For the three months ended March 31, 2026, collaboration revenue was $19,635 thousand, up from $1,573 thousand a year earlier.
Total operating expenses rose to $36,915 thousand from $9,025 thousand, driven by higher research and development and general and administrative spending. Atrium recorded a net loss of $16,633 thousand, versus $7,449 thousand in the prior-year period, equal to a basic and diluted net loss per share of $0.97 compared with $0.44.
On the balance sheet as of March 31, 2026, cash and cash equivalents were $267,849 thousand, total assets were $292,360 thousand, and total liabilities were $58,256 thousand, resulting in stockholders’ equity of $234,104 thousand.